Skip to main content

What is the difference between Soliqua and Xultophy?

Medically reviewed by Leigh Ann Anderson, PharmD. Last updated on March 8, 2024.

Official answer

by Drugs.com

Both products combine a long-acting insulin with a GLP-1 agonist – Xultopy brings together Tresiba (insulin degludec) and Victoza (liraglutide), while Soliqua combines Lantus (insulin glargine) with Adlyxin (lixisenatide).

Soliqua 100/33 is Sanofi’s once-daily injection used alongside diet and exercise to improve blood sugar control in adults type 2 diabetes. Soliqua 100/33 is a combination of insulin glargine 100 Units/mL (Lantus), a long-acting insulin, and lixisenatide 33 mcg/mL (Adlyxin), a glucagon-like peptide-1 (GLP-1) agonist.

Xultophy 100/3.6 is Novo Nordisk’s once-daily injection of insulin degludec 100 Units/mL (Tresiba), and the GLP-1 agonist liraglutide 3.6 mg/mL (Victoza), also used to treat type 2 diabetes in conjunction with diet and exercise. Insulin degludec is a long-acting insulin and liraglutide is a glucagon-like peptide-1 (GLP-1) agonist.

These two medications, available as injection pens, were the first approved in a novel group of type 2 diabetes treatments that combine a long-acting insulin with a GLP-1 agonist. They are not approved for the treatment of type 1 diabetes. These drugs are often used after other diabetes medications have been tried without success.

Long-acting insulins start working several hours after injection and continue to work steadily for 24 hours. Glucagon-like peptide-1 (GLP-1) agonists are similar to a hormone that occurs naturally in the body and helps to control blood sugar, insulin levels, and digestion. GLP-1 agonists may help you to lose weight.

GLP-1 agonists approved in the U.S. include:

  • albiglutide (Tanzeum)
  • dulaglutide (Trulicity)
  • exenatide extended-release (Bydureon BCise)
  • exenatide (Byetta)
  • liraglutide (Victoza)
  • lixisenatide (Adlyxin)
  • semaglutide (Ozempic)
  • semaglutide (Rybelsus)

All agents are given by injection except for Rybelsus from Novo Nordisk, the first oral GLP-1 agonist, approved in September 2019.

This is not all the information you need to know about Xultophy or Soliqua for safe and effective use and does not take the place of talking to your doctor about your treatment. Review the full product information, and discuss this information and any questions you have with your doctor or other health care provider.

Related questions

References

Read next

What's the easiest way to open a Rybelsus bottle?

Step-by-step guide to open your bottle of Rybelsus: 1. Wash and dry your hands thoroughly. 2. Find the child-resistant blue cap on the top of the Rybelsus bottle. 3. Look for markings on the bottle cap that show which way to twist the cap to open. Hold the blue cap tightly, push down and twist the cap in a counter-clockwise direction. The cap should separate from the white plastic strip below it and twist open. Continue reading

What is the mechanism of action for Rybelsus?

Rybelsus works for your type 2 diabetes in three ways: it helps to reduce your blood sugar levels by increasing insulin, it decreases the amount of sugar made and released from the liver, and it slows down how fast food leaves your stomach to help you feel more full. Continue reading

How and where do you inject liraglutide?

Liraglutide is injected just under the skin (subcutaneously) and the best sites are your stomach (abdomen), thigh, or upper arm. Do not inject Victoza into a muscle (intramuscularly) or vein (intravenously). To do this, you pinch up an area of skin with your thumb and forefinger, and then push the needle of the pen into this area, so that the medication will be injected just under the skin. Ask your doctor, nurse, or pharmacist to show you how to use the pen correctly before your first use. Continue reading

Related medical questions

Related support groups